Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2026

Conditions
Acute Myelocytic Leukemia
Interventions
BIOLOGICAL

Unrelated umbilical cord blood

The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.

DRUG

Venetoclax

Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)

DRUG

Decetabine

Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)

DRUG

Azacitidine

Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)

Trial Locations (1)

230001

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV